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Chikungunyainfectionhasrecentlyre-emergedasanimportantarthropod-bornediseaseinThailand.Recently,SouthernThailand
was identiﬁed as a potentially endemic area for the chikungunya virus. Here, we report a case of severe musculoskeletal
complication, presenting with muscle weakness and swelling of the limbs. During the investigation to exclude autoimmune
muscular inﬂammation, high titers of antinuclear antibody were detected. This is the report of autoimmunity detection associated
with an arbovirus infection. The symptoms can mimic autoimmune polymyositis disease, and the condition requires close
monitoring before deciding to embark upon prolonged speciﬁc treatment with immunomodulators.
Copyright © 2009 W. Maek-a-nantawat and U. Silachamroon. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
1.Introduction
Chikungunya is a mosquito-borne arboviral infection. The
virus can be epidemic and is endemic in Africa, India, the
Indian Ocean islands, and Southeast Asia [1–3]. It has been
reported sporadically from some provinces in Thailand [4],
in 1988, 1991, and 1993, since its ﬁrst detection in Bangkok,
in 1958 [5, 6]. From late 2008 to the time of writing, the
cumulative reported patient numbers reached a peak of
over 20000 cases. This infection is not uncommon, and
sometimes must be included in the diﬀerential diagnosis of
dengue. This paper shows a distinguishing manifestation of
chikungunya, which may assist in the diﬀerential diagnosis
from autoimmune inﬂammatory myopathies.
2.CaseReport
A 21-year-old female from Yala Province, Southern Thai-
land, presented with high-grade fever during a vacation in
Bangkok. She developed fever, polyarthralgia, and polymyal-
gia for 5 days; generalized erythematous rash was noted
1 day preadmission. She had no known underlying or
familial disease, and no history of hair loss, oral ulcer,
or photosensitivity. She denied traveling, or exposure to
cattle, ﬂooding, goat dairy products, unusual foods, or pets.
Physical examination on admission showed temperature
38.6
◦C, BP 105/60mmHg, PR 98/min, RR 24/min, mildly
dehydrated lips, bilateral injected conjunctivae, bilateral
palpable cervical lymph nodes ∼0.5–1cm in diameter, with
predominant tenderness on the left postauricular nodes,
and pain in the calves and joints of the extremities. Nor-
mal cardiovascular, pulmonary, and neurological ﬁndings
were noted. Only a just-palpable, soft liver was noted on
abdominal examination. CBC on admission (D0) is shown
in Table 1. Her symptoms were alleviated by analgesics (for
pain) and paracetamol (antipyretic). She was presumptively
diagnosed with leptospirosis and began treatment with
2gm/day of ceftriaxone.
However, more aggravated joint and muscle pain, with
particular digital swellings at both hands and feet, were
reported the following day. Physical examination supported
this clinically, with puﬀy hands and feet with marked tender-
ness at the bilateral knuckles, including the metacarpopha-
langeal(MCP),distalandproximalinterphalangeal(DIPand
PIP) joints, and proximal muscle weakness in both upper
and lower extremities. CBC and blood chemistry analysis
the following day (D2) are shown in Table 1. Urine analysis
found a yellow, clear ﬂuid, speciﬁc gravity 1.020, pH 6.5,
protein 0.0075g/L, glucose negative, WBC 0-1/HPF, RBC
3–5/HPF, and epithelium 0-1/HPF. There was no evidence2 Case Reports in Medicine
Table 1: Summary of laboratory investigations.
Investigations D1 D2 D5 D10 M1 M3 Normal range
Hemoglobin (g/dL) 13.1 11.8 11.0 10.8 12.8 13.2 12–16
hematocrit (%) 39.2 34.8 31.5 32.3 37.1 39.8 37–47
MCV (fL) 90.7 91.2 86.2 89.2 91.3 92.3 82–96
WBC (×103/μL) 14.8 17.5 12.0 15.0 11.3 8.9 5.0–10.0
Neutrophils (%) 87 90 76 88, Band 3% 80 77 45–74, Band 0–4%
Lymphocytes (%) 4 4 6 5 14 21 16–45
Monocytes (%) 6 5 9 2 3 2 4–10
Eosinophils (%) 2 1 7 — 2 — 0–7
Basophils (%) 1 — — — 1 — 0–2
Atypical lymphocytes (%) — — 2 2 — — 0–5
Platelets (×103/μL) 268 286 545 839 344 389 150–450
Urea nitrogen (mmol/L) 4.64 3.927 2.86 — — — 3.6–7.1
Creatinine (μmol/L) 61.88 53.04 44.2 — — — 53–88
Glucose (mmol/L) — 6.22 — — 5.1 — 4.2–6.4
AST (μkat/L) 1.75 2.15 2.02 0.92 0.52 0.55 0.1–0.66
ALT (μkat/L) 2.33 2.28 1.95 1.42 0.46 0.56 0.1–0.66
Alkaline phosphatase (U/L) 119 101 92 — — — 50–136
Total bilirubin (μmol/L) 13.9 10.94 8.55 — — — 5.1–17
Total protein (g/L) 70.8 68 66 — — — 64–82
Albumin (g/L) 35.1 36 30 — — — 34–50
Sodium (μmol/L) 130 131 130 — — — 136–145
Potassium (μmol/L) 3.65 3.8 3.5 — — — 3.5–5.0
Chloride (μmol/L) 97 91 89 — — — 98–107
Bicarbonate (μmol/L) 22 25 27 — — — 23–29
Creatinine kinase (μkat/L) — — 16.35 10.22 1.22 1.04 0.17–1.17
Uric acid (μmol/L) — — 208.18 — — — 90–360
of hemolysis proven by direct microscopic blood ﬁlm slide
and Coomb’s test negative. Serological tests were conducted
for possible infections, including chikungunya disease. The
IgM rapid chikungunya test and IgG using HAI both showed
negative. IFA tests for scrub typhus and murine typhus
showed negative for IgM and IgG. IFA tests for leptospiral
antibody IgM and IgG were negative. However, serology for
dengue infection and lyme disease were not tested because
of not compatible clinical feature and endemicity of the
diseases.
Three days later, the patient looked edematous and an
erythematous rash had spread throughout her body. Physical
examination revealed progressive painful joints and digits.
Shehadtostayinbedbecauseshewasunabletogetupfroma
proneposition.CBCandbloodchemistryresultsonday5are
shown in Table 1.E l ev a t e dm u s c l ee n z ym ew a sd e t e ct e d .E S R
was 83mm/hr. Urine analysis found a yellow clear ﬂuid with
speciﬁc gravity 1.015, pH 6.0, protein 0.0025g/L, glucose
negative, WBC 1-2/HPF, RBC 1-2/HPF, and epithelium
0-1/HPF. Hemocultures of 3 specimens showed negative.
Secondary causes of polymyositis were assessed. Anti-HIV
antibody was negative. Intravenous ceftriaxone was discon-
tinued. High-dose steroid treatment was initiated to control
inﬂammation, with 20mg/day of dexamethasone, which was
switched to 0.8mg/kg/D oral prednisolone. After 3–5 days of
steroid treatment, a signiﬁcant clinical response was noted.
She became afebrile, reported reduced pain in the joints, and
resumed normal life after 1 week of treatment. CBC and
blood chemistry results on D10 are shown in Table 1.E S R
was 64mm/hr.
Serological testing conﬁrmed acute chikungunya infec-
tion by EIA IgM 338 Units, IgG 15 Units. Serological tests
were run each week, after the rapid tests. Other immunolog-
ical laboratory investigations showed antinuclear antibody
positive 1 : 320, speckled typed, anti-dsDNA negative,
anti-SM negative, anti-JO-1 negative, VDRL nonreactive,
and rheumatoid factor negative. Four to six weeks later,
the patient improved markedly and resumed her normal
activities. Steroid dosage was tapered oﬀ 10–15mg/D every
2 weeks, and discontinued at 10 weeks. Antinuclear antibody
levels were tested repeatedly and became negative 3 months




it is necessary to explore the patient’s medical history
and assess exposure to risk, when no localized symptomsCase Reports in Medicine 3
or signs are detected in a systemic infection. Labora-
tory screening investigations showed leukocytosis without
thrombocytopenia coincidently with liver involvement in
systemic illness. No speciﬁc liver or kidney injury was
indicated.Leukocytosiscansometimesbefoundinearlyviral
infections, and atypical bacterial infections in the tropics,
such as leptospirosis, rickettsiosis, tuberculosis, including
nontuberculous mycobacteria, and melioidosis, must be
ruled out. Some animal-associated and toxin-producing
bacterialinfectionsshouldnotbemissedbyextensivehistory
review and clinical clues on the skin, eyes, mucosal, and
musculoskeletal parts. The absence of thrombocytopenia,
suggested that dengue or other hemorrhagic fever, and
malaria, could probably be excluded. Followup complete-
blood-count tests found atypical lymphocytes, supporting
the suspicion of viral infection. Patient residence details can
also point to a current outbreak of “Chikungunya infection”
or simply, “CHIK.”
Chikungunya is screened by asking for possible symp-
toms in the list of diseases under investigation, including
highfever,headache,myalgia,arthralgia,conjunctivitis,peri-
orbital pain, joint swelling, erythematous rash, and petechial
spots. Polyarthralgia and generalized myalgia were reported
in nearly all cases (96 and 79%, resp.), while puﬀy hands and
feet were found in only 19 and 16% of cases, respectively [7].
Serological tests can help establishing a diagnosis. Repeated
laboratory tests are necessary in suspicious cases, even when
the rapid screening test shows negative. Important clues are
severe polymyositis and polyarthritis, especially of the small
joints of the hands and the wrists, which are infrequently
found in autoimmune rheumatism, apart from rheumatoid
arthritis.Apresentationofbilateralandsymmetricalarthritis
involving the hands and wrists, mimicking rheumatoid
arthritis, may be resolved with seronegative rheumatoid
factor and a medical history pointing to acute infection.
Rheumatoid factor was reported positive in around 8–13%
of chikungunya cases [7]. Followup investigations implied
massive continuing inﬂammation, such as anemia with
thrombocytosis, and elevatederythrocyte sedimentation rate
(ESR). However, seropositivity for antinuclear antibodies
was uncommonly detected in systemic infections, especially
in a context of high titer dilution. Although several viral
infections, such as Epstein-Barr virus (EBV), hepatitis virus,
and cytomegalovirus (CMV), were reported to coexist with
positive antinuclear antibodies [8] and the etiopathogenesis
ofautoimmunedisease[9],chikungunyahasnotbeenfound.
This is the ﬁrst case report of autoimmune anti-
body detected during chikungunya infection and its dis-
appearance postresolution. The existence of autoimmunity
might explain the debilitating and prolonged aggravating
musculoskeletal manifestation resulting from chikungunya
infection in asymptomatic or early autoimmune disease.
It remains to be elucidated why seropositivity lapsed with
patient cure. In the current case, the patient’s baseline
immunostatus was unknown. It is probable that immune
activation resulting from massive inﬂammation occurs
simultaneously with viral cellular immune responses [10]
and B-cell polyclonal activation against the host. Progression
to clinical deterioration is triggered by viral replication,
via proposed molecular mimicry [11]. There was only a
temporal association between chikungunya infection and
antinuclear antibodies in this interesting case report.
Good responses to high doses of steroids have been
reported in many cases of arthropathy [12]. The actions
of steroids in regulating gene function and inactivating
the related proteins involving proinﬂammatory cytokines
attenuate inﬂammatory myopathy. However, many deaths
can be attributed to drugs (e.g., steroids) prescribed to
treat symptoms [13]. The virus replicates in the endothelial
cells, monocytes and macrophages in the lymph nodes,
bone marrow, spleen, and liver. Viral mutation leads to new
complications, such as hepatitis, cerebral meningitis, and
coma, which have resulted in several deaths [14]. Proof of
thebeneﬁtsofcorticosteroidsandchloroquinewouldrequire
a controlled study. Colchicine and chloroquine may be used
as adjunct drugs.
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